Affiliations: [a] Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, TX, USA
| [b] Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA
Correspondence:
[*]
Correspondence to: Sid O’Bryant, PhD, University of North Texas Health Science Center, Fort Worth, TX, USA. Tel.: +1 817 735 2962; E-mail: sid.obryant@unthsc.edu.
Note: [1] HABS-HD Study Team: MPIs: Sid E O’Bryant, Kristine Yaffe, Arthur Toga, Robert Rissman and Leigh Johnson; and the HABS-HD Investigators: Meredith Braskie, Kevin King, Matthew Borzage, James R Hall, Melissa Petersen, Raymond Palmer, Robert Barber, Yonggang Shi, Fan Zhang, Rajesh Nandy, Roderick McColl, David Mason, Bradley Christian, Nicole Philips and Stephanie Large.
Abstract: Background:Despite the tremendous amount of research on Alzheimer’s disease (AD) biomarkers, very little data is available regarding the fundamental biomarkers of AD among Mexican Americans. Objective:Here we sought to examine the link between metabolic markers and brain amyloid among Mexican Americans as compared to non-Hispanic whites from the Health & Aging Brain Study –Health Disparities (HABS-HD) cohort. Methods:PET amyloid (florbetaben) data was analyzed from 34 Mexican American and 22 non-Hispanic white participants. Results:Glucagon (t = 3.84, p < 0.001) and insulin (t = –2.56, p = 0.02) were both significantly related to global SUVR levels among Mexican Americans. Glucagon and insulin were both related to most ROIs. No metabolic markers were significantly related to brain amyloid levels among non-Hispanic whites. Conclusion:Metabolic markers are related to brain amyloid burden among Mexican Americans. Given the increased risk for diabetes, additional research is needed to determine the impact of diabetes on core AD biomarkers among this underserved population.
Keywords: Alzheimer’s disease, amyloid, health disparities, Hispanic
